Our Company
We are a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS)
Leveraging a Critical Pathway
Cyclerion was founded with the goal of unlocking the full therapeutic potential of the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway. Nitric oxide (NO) is one of several fundamental neurotransmitters, but it has yet to be leveraged for its full therapeutic potential in the central nervous system (CNS). As such, we believe our approach to enhancing NO-cGMP signaling – sGC stimulation – has broad potential to treat serious diseases of the CNS. We are excited and motivated by this opportunity to bring new medicines to patients in need.
Startup Spirit, Mature Biotech Expertise
Founded in April 2019, Cyclerion is an independent, publicly traded company working at the forefront of CNS drug development. Our mission is to develop innovative medicines that improve brain function for patients in desperate need of new treatment options. The NO-sGC-cGMP signaling pathway is critical to basic neuronal function and overall brain health, and impaired NO-sGC-cGMP-signaling is believed to play an important role in the pathogenesis of many neurodegenerative diseases. We are building on a growing body of data about this pathway to advance a pipeline for serious diseases of the CNS.
We pursue this mission with the emboldened spirit, passionate culture, and drive of a startup, while bolstered by the expertise and leadership of a mature biotech.
Value-Creating Enablers
Our strategy to deliver impact to patients and create value for stockholders rests on a solid scientific foundation that is enabled by our people and capabilities, external collaborators, and a responsive capital allocation approach.
Experience in central nervous system diseases
Our team has diverse experience across discovery, pre-clinical evaluation, clinical development and registration of CNS therapies, including neurodegenerative, neuromuscular, neuropsychiatric, pain epilepsy and various rare CNS indications.
Leaders in nitric oxide-cGMP pathway pharmacology
Our team has deep knowledge and significant experience in cGMP pathway research and development. This experience encompasses the discovery and development of linaclotide, an Ironwood Pharmaceuticals product that leverages the pharmacology of the guanylate cyclase-C-cGMP pathway, and the development of the sGC stimulator chemistry libraries and systems pharmacology data that gave rise to the current portfolio of assets that are the foundation for our innovation at Cyclerion.
Exceptional team with proven track record of delivering innovative therapies
We have broad expertise throughout our organization in discovering, developing, and commercializing category-leading products, and are led by a management team with a history of successfully delivering innovative therapies to patients while creating value for stockholders.
We leverage a diverse cross-disciplinary network of external advisors and experts to advance our CNS program. We do this by:
- Engaging leading experts to access additional technologies and expertise to advance our programs
- Establishing advisory boards of physicians, patients and payors to provide insights into the unmet medical need and to support the design of clinical trials
- Consulting scientific advisory boards made up of veteran drug hunters with broad industry experience and a track record of innovation
We will apply a ‘‘best-owner’’ approach to our compounds whereby we develop and commercialize product candidates independently or through a partner depending on which path we believe will accelerate global patient access to our drugs and offer the greatest risk-adjusted value for our stockholders. We intend to prioritize development and commercialization in CNS diseases characterized by structurally attractive markets where we can successfully commercialize on our own. We define structurally attractive markets as those managed by a narrow prescriber base with clear unmet patient need, payor willingness to pay, and the potential for first-in-class entry.
To inquire about partnering with Cyclerion, please reach out to us at partnering@cyclerion.com.
The capital allocation decision making and financial management we use in our business is designed to enable us to continually deploy capital and people to the most promising opportunities.